PTPN11 and pancreatic neoplasm: To determine whether the observed metabolic properties following SHP2/MEK inhibition prove true in vivo, we treated KPC mice, monitored the pancreatic tumor volume via magnetic resonance imaging (MRI), and collected tumor interstitial fluid (TIF).